medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2016, Número 2

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (2)


Proteinuria en gammapatías monoclonales

Miguel MM, Agramonte LOM

Idioma: Español
Referencias bibliográficas: 56
Paginas: 160-175
Archivo PDF: 315.45 Kb.


RESUMEN

La presencia de proteínas en la orina se denomina proteinuria, en adultos se define clínicamente por una excreción urinaria de proteínas superior a 150 mg en 24 horas y se produce por una alteración en la barrera de filtración glomerular, que permite el escape de las proteínas en la orina. La proteinuria es frecuente en diferentes enfermedades, particularmente en las gammapatías monoclonales. Los criterios para el diagnóstico de estas entidades incluyen la presencia de células plasmáticas anormales en la médula ósea, una proteína monoclonal en suero aumentada, una proteína monoclonal en orina o lesiones osteolíticas. Para el diagnóstico, evaluación y monitoreo del tratamiento de las gammapatías monoclonales se realizan los estudios electroforéticos de proteínas plasmáticas o proteinogramas séricos y urinarios, técnica que permite la separación de proteínas en función de su migración diferencial al ser sometidas a un campo eléctrico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dimopulos MA, Kastritis E, Rosnol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485-93.

  2. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 2011; 29:674– 81. doi: 10.1200/JCO.2010.30.5235.

  3. García-Sanz R, Mateos MV, San Miguel JF. Mieloma múltiple. Med Clin (Barc). 2007; 129(3):104-15.

  4. San Miguel J. Multiple myeloma: a model for scientific and clinical progress. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):1-7. doi: 10.1182/asheducation-2014.1.1.

  5. Pallin DJ, Ronan C, Montazeri K, Wai K, Gold A, Parmar S, et al. Urinalysis in acute care of adults: pitfalls in testing and interpreting results. Open Forum Infect Dis. 2014 Jun 23;1(1):ofu019. doi: 10.1093/ofid/ofu019. eCollection 2014.

  6. Hemmelgarn BR, Manns BJ, Lloyd A,Klarenbach S,Quinn RR, Wiebe N, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010; 303: 423–9.

  7. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008; 74:101–7.

  8. Ulate G. Fisiología renal. San José: Editorial de la Universidad de Costa Rica. 2006.

  9. Caridi G, Zoccali C. Pathogenesis of renal failure in hypertension. The role of genetic factors, low weight at birth and endothelial dysfunction. Recenti Prog Med. 2005 Apr;96(4):205-10.

  10. Eravica R, Aabarkapa V, Ilinčić B, Sakač V, Mijović R, Nikolić S, et al. Plasma endothelin-1 level, measured glomerular filtration rate and effective renal plasma flow in diabetic nephropathy. BMC Nephrol 2015 Feb 17:1-6.

  11. Mazzoni MB, Kottanatu L, Simonetti GD, Ragazzi M, Bianchetti MG, Fossali EF, et al. Renal vein obstruction and orthostatic proteinuria: a review. Nephrol Dial Transplant. 2011 Feb;26(2):562-5. doi: 10.1093/ndt/gfq444.

  12. Lamb EJ, MacKenzie F, Stevens PE. How should Proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205–17.

  13. Torffvit O, Melander O, Hulten U. Urinary excretion rate of Tamm- Horsfall protein is related to salt intake in humans. Nephron Physiol. 2004; 97: 31-36.

  14. Devuyst O, Dahan K, Pirson Y. Tamm–Horsfall protein or uromodulin: new ideas about an old molecule. Nephrology dialysis transplantation. 2005 Jul; 20:1290-4.

  15. Tryggvason K, Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med. 2003; 254:216-24.

  16. D’Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003; 63: 809 -25.

  17. Lambers HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010;21:1355-60.

  18. Venkat K. Proteinuria and microalbuminuria in adults: Significance, evaluation and treatment. Southern Medical J. 2004; 97: 969 -78.

  19. Joly D, Choukroun G, Combe C, Dussol B, Fauvel JP, Halimi JM, et al. Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: A prospective observational study. Diabetes Res Clin Pract. 2015 Apr;108(1):120-7. doi: 10.1016/j.diabres.2015.01.029.

  20. Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003; 41(3): 338-46.

  21. Yesil EE, Paker N, Yesil A, Kayatas K, Laleli Y, Ari E. Urinary gamma-glutamyl transferase-to-creatinine ratio as an indicator of tubular function in Bence Jones proteinuria. Ren Fail. 2014 Apr; 36(3):390-2. doi:10.3109/0886022X.2013.867784.

  22. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative κ and λ free light Caín assays in clinical practice. Clin Chem. 2005; 51(5):878-81.

  23. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: Results from t he NHANES III. Kidney Int 2002; 61:2165-75.

  24. Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, Usha Multiple myeloma--presenting as acute kidney injury. Assoc Physicians India. 2009 Jan; 57:23-6.

  25. Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Hernández-Reyes J, Martagón- Herrera NA, Ruiz-Argüelles A, Ruiz-Delgado GJ, et al. Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma. Rev Invest Clin. 2014 Jul-Aug;66(4):314-8.

  26. Camaré C, Caussé E. Urinary protein electrophoresis, which analysis to select? A simplified interpretation. Ann Biol Clin (Paris). 2013 Nov-Dec; 71(6):667-78. doi: 10.1684/abc.2013.0913.

  27. Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ 2006; 332:94.

  28. Nisell H, Trygg M, Back R. Urine albumin/creatinine for the assessment of albuminuria in pregnancy hypertension. Acta Obstet Gynecol Scand 2006;85:1327

  29. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007; 50:169-80.

  30. Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, Usha. Multiple myeloma--presenting as acute kidney injury. J Assoc Physicians India. 2009 Jan;57:23-6.

  31. Bergón E, Granados R, Fernández-Segoviano P, Miravalles E, Bergón M. Classification of renal proteinuria: a simple algorithm. Clin Chem Lab Med. 2002 Nov; 40(11):1143-50.

  32. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of Acute Kidney Injury. Ann Rev Pharmacol Toxicol. 2008; 48:463–93.

  33. Iseki K. Proteinuria and the risk of developing end stage renal disease. Kidney Int. 2003; 63: 1468-74.

  34. Hart P. Maximum reduction of proteinuria in renal disease. Kidney. 2004; 13:99 – 103.

  35. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant.2003;18:2170-4.

  36. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: Results from t he NHANES III. Kidney Int.2002;61:2165-75.

  37. Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, Gatsiou A,et al. Amyloid-Beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015 Mar 10;65(9):904-16. doi: 10.1016/j.jacc.2014.12.035.

  38. Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ. 2006;332:94.

  39. Suvannasankha A, Chirgwin JM. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res. 2014 Dec 31;16(6):484.

  40. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341: c4986.

  41. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423-9.

  42. Van der Velde M, Halbesma N, de Charro FT, Bakker SJL, de Zeeuw D, de Jong PE, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol. 2009;20:852-62.

  43. Rojas-Torres DS, Bastidas-Yaguana DK, Sierra-Santos L, Aguilar-Shea AL Importance of selective immunoglobulin A deficiency. Semergen. 2014 Apr;40(3):e65-8. doi: 10.1016/j.semerg.2013.01.013.

  44. Wu M, Zhang F, Liang Y, Wang R, Chen Z, Lin J, et al. Isolation and purification of immunoglobulin G from bovine colostrums by hydrophobic charge-induction chromatography. J Dairy Sci. 2015 Mar 5. pii: S0022-0302(15)00156-3. doi: 10.3168/jds.2014-9142.

  45. Choi JH, Jang YS, Oh JW, Kim CH, Hyun IG. Bee Pollen-Induced Anaphylaxis: A Case Report and Literature Review. Allergy Asthma Immunol Res. 2014 Oct 15.

  46. Udla V, Pika T, Minařík J. The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies. Vnitr Lek. 2015 Jan;61(1):60-71.

  47. Eckold J, Poenisch W, Drogies T, Kratzsch J, Teupser D, Thiery J, et al Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies. Clin Lab. 2014; 60(9):1491-500.

  48. Stelmach-Gołdyś A, Czarkowska-Paczek B. Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma Przegl Lek. 2012;69(5):194-6.

  49. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. International Kidney and Monoclonal Gammopathy Research Group Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012 Nov 22; 120(22):4292-5. doi: 10.1182/blood-2012-07- 445304.

  50. Faiman BM, Mangan P, Spong J, Tariman JD, The International Myeloma Foundation Nurse Leadership Board . Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011 Aug; 15 Suppl:66-76. doi: 10.1188/11

  51. Mian M, Franz I, Wasle I, Herold M, Griesmacher A, Prokop W, et al "Idiopathic Bence-Jones proteinuria": a new characterization of an old entity. Ann Hematol. 2013 Sep;92(9):1263-70. doi: 10.1007/s00277-013-1739-8.

  52. Todinova S, Krumova S, Radoeva R, Gartcheva L, Taneva SG Calorimetric markers of Bence Jones and nonsecretory multiple myeloma serum proteome. Anal Chem. 2014 Dec 16;86(24):12355-61. doi: 10.1021/ac503677d.

  53. Kasi PM, Ansell SM, Gertz MA. Waldenstrom macroglobulinemia. Clin Adv Hematol Oncol. 2015 Jan;13(1):56-66.

  54. Liu SJ,Zhai YP,Yu YP,Liu HN,Li F, Song P, et al. Significance of low molecular weight urinary protein for assessment of early renal damage in patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):410-4. doi: 10.7534/j.issn.1009-2137.2013.02.031.

  55. Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, et al; International Kidney and Monoclonal Gammopathy Research Group How I treat monoclonal gammopathy of renal significance (MGRS). Blood.2013 Nov; 122(22):3583-90. doi: 10.1182/blood-2013-05-495929.

  56. Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, et al. The Greek Myeloma Study Group. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol. 2014 Apr;92(4):308-12. doi: 10.1111/ejh.12255.




2020     |     www.medigraphic.com